210 related articles for article (PubMed ID: 22160032)
1. New insights into therapeutic targets in myeloma.
Anderson KC
Hematology Am Soc Hematol Educ Program; 2011; 2011():184-90. PubMed ID: 22160032
[TBL] [Abstract][Full Text] [Related]
2. Novel targeted agents in the treatment of multiple myeloma.
Varga C; Laubach J; Hideshima T; Chauhan D; Anderson KC; Richardson PG
Hematol Oncol Clin North Am; 2014 Oct; 28(5):903-25. PubMed ID: 25212889
[TBL] [Abstract][Full Text] [Related]
3. Contemporary drug therapies for multiple myeloma.
de la Puente P; Azab AK
Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
[TBL] [Abstract][Full Text] [Related]
4. Novel therapeutic targets in multiple myeloma.
Cottini F; Anderson K
Clin Adv Hematol Oncol; 2015 Apr; 13(4):236-48. PubMed ID: 26352582
[TBL] [Abstract][Full Text] [Related]
5. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibodies in myeloma.
Sondergeld P; van de Donk NW; Richardson PG; Plesner T
Clin Adv Hematol Oncol; 2015 Sep; 13(9):599-609. PubMed ID: 26452191
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions.
Anderson KC
Exp Hematol; 2007 Apr; 35(4 Suppl 1):155-62. PubMed ID: 17379101
[TBL] [Abstract][Full Text] [Related]
8. Management of myeloma: an Italian perspective.
Bruno B; Gay F; Boccadoro M; Palumbo A
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1():S82-6. PubMed ID: 22035755
[TBL] [Abstract][Full Text] [Related]
9. Identification and validation of novel therapeutic targets for multiple myeloma.
Hideshima T; Chauhan D; Richardson P; Anderson KC
J Clin Oncol; 2005 Sep; 23(26):6345-50. PubMed ID: 16155018
[TBL] [Abstract][Full Text] [Related]
10. Update on targeted cancer therapies, single or in combination, and their fine tuning for precision medicine.
Bashraheel SS; Domling A; Goda SK
Biomed Pharmacother; 2020 May; 125():110009. PubMed ID: 32106381
[TBL] [Abstract][Full Text] [Related]
11. Relapsed and refractory multiple myeloma: new therapeutic strategies.
Gentili S; Lonial S
Hematol Oncol Clin North Am; 2014 Oct; 28(5):861-90. PubMed ID: 25212887
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies - A new era in the treatment of multiple myeloma.
Jelinek T; Hajek R
Blood Rev; 2016 Mar; 30(2):101-10. PubMed ID: 26362528
[TBL] [Abstract][Full Text] [Related]
13. Novel therapeutic strategies for multiple myeloma.
Mimura N; Hideshima T; Anderson KC
Exp Hematol; 2015 Aug; 43(8):732-41. PubMed ID: 26118499
[TBL] [Abstract][Full Text] [Related]
14. Immunologic microenvironment and personalized treatment in multiple myeloma.
Rossi M; Botta C; Correale P; Tassone P; Tagliaferri P
Expert Opin Biol Ther; 2013 Jun; 13 Suppl 1():S83-93. PubMed ID: 23692463
[TBL] [Abstract][Full Text] [Related]
15. Monoclonal antibodies in the treatment of multiple myeloma.
Richardson PG; Lonial S; Jakubowiak AJ; Harousseau JL; Anderson KC
Br J Haematol; 2011 Sep; 154(6):745-54. PubMed ID: 21777223
[TBL] [Abstract][Full Text] [Related]
16. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings.
Richardson PG; Laubach J; Mitsiades CS; Schlossman R; Hideshima T; Redman K; Chauhan D; Ghobrial IM; Munshi N; Anderson KC
Br J Haematol; 2011 Sep; 154(6):755-62. PubMed ID: 21732930
[TBL] [Abstract][Full Text] [Related]
17. AKT as a therapeutic target in multiple myeloma.
Keane NA; Glavey SV; Krawczyk J; O'Dwyer M
Expert Opin Ther Targets; 2014 Aug; 18(8):897-915. PubMed ID: 24905897
[TBL] [Abstract][Full Text] [Related]
18. [New drugs in the treatment of multiple myeloma].
Oriol A; Motlló C
Med Clin (Barc); 2014 Sep; 143(6):268-74. PubMed ID: 24342015
[TBL] [Abstract][Full Text] [Related]
19. Oncogenomics to target myeloma in the bone marrow microenvironment.
Anderson KC
Clin Cancer Res; 2011 Mar; 17(6):1225-33. PubMed ID: 21411438
[TBL] [Abstract][Full Text] [Related]
20. Panobinostat for the treatment of relapsed or relapsed/refractory multiple myeloma: pharmacology and clinical outcomes.
Richardson PG; Harvey RD; Laubach JP; Moreau P; Lonial S; San-Miguel JF
Expert Rev Clin Pharmacol; 2016; 9(1):35-48. PubMed ID: 26503877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]